JP2018527912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527912A5 JP2018527912A5 JP2018506135A JP2018506135A JP2018527912A5 JP 2018527912 A5 JP2018527912 A5 JP 2018527912A5 JP 2018506135 A JP2018506135 A JP 2018506135A JP 2018506135 A JP2018506135 A JP 2018506135A JP 2018527912 A5 JP2018527912 A5 JP 2018527912A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 114
- 102000036639 antigens Human genes 0.000 claims description 114
- 108091007433 antigens Proteins 0.000 claims description 114
- 239000012634 fragment Substances 0.000 claims description 113
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 22
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 19
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 208000035473 Communicable disease Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 210000000822 natural killer cell Anatomy 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 8
- 102000025171 antigen binding proteins Human genes 0.000 description 6
- 108091000831 antigen binding proteins Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201506227V | 2015-08-06 | ||
| SG10201506227V | 2015-08-06 | ||
| PCT/EP2016/068780 WO2017021540A1 (en) | 2015-08-06 | 2016-08-05 | Il2rbeta/common gamma chain antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018527912A JP2018527912A (ja) | 2018-09-27 |
| JP2018527912A5 true JP2018527912A5 (OSRAM) | 2019-09-19 |
| JP6908591B2 JP6908591B2 (ja) | 2021-07-28 |
Family
ID=56889037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506135A Active JP6908591B2 (ja) | 2015-08-06 | 2016-08-05 | Ｉｌ２ｒベータ／共通ガンマ鎖抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10167338B2 (OSRAM) |
| EP (2) | EP3328894B1 (OSRAM) |
| JP (1) | JP6908591B2 (OSRAM) |
| KR (1) | KR102753399B1 (OSRAM) |
| CN (2) | CN107922496B (OSRAM) |
| AU (1) | AU2016301970A1 (OSRAM) |
| CA (1) | CA2994906A1 (OSRAM) |
| CY (1) | CY1121197T1 (OSRAM) |
| DK (1) | DK3328894T3 (OSRAM) |
| ES (2) | ES2710618T3 (OSRAM) |
| HU (1) | HUE043421T2 (OSRAM) |
| PL (1) | PL3328894T3 (OSRAM) |
| PT (1) | PT3328894T (OSRAM) |
| TR (1) | TR201901445T4 (OSRAM) |
| TW (1) | TW201713699A (OSRAM) |
| WO (1) | WO2017021540A1 (OSRAM) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2712655B1 (en) | 2011-04-28 | 2019-12-18 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| DK3328894T3 (en) | 2015-08-06 | 2019-02-04 | Agency Science Tech & Res | IL2RBETA / COMMON GAMMA CHAIN ANTIBODIES |
| CA3026180A1 (en) | 2016-06-10 | 2017-12-14 | Gadeta B.V. | Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof |
| EP3624823A1 (en) | 2017-05-18 | 2020-03-25 | UMC Utrecht Holding B.V. | Compositions and methods for cell targeting therapies |
| CN111954680B (zh) * | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| WO2019178518A1 (en) * | 2018-03-16 | 2019-09-19 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
| EP3796977A4 (en) * | 2018-05-17 | 2022-03-02 | The Board of Trustees of the Leland Stanford Junior University | RECEPTOR INHIBITION BY PHOSPHATASE RECRUITMENT |
| KR20210055070A (ko) * | 2018-08-06 | 2021-05-14 | 메디카인 인코포레이티드 | Il-2 수용체 결합 화합물 |
| CA3108949A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| AU2019328575B2 (en) | 2018-08-30 | 2024-07-11 | Immunitybio, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| JP7407822B2 (ja) | 2018-08-30 | 2024-01-04 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 単鎖キメラポリペプチドおよびその使用 |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| TW202039557A (zh) | 2018-11-09 | 2020-11-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| WO2020094834A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| CN120157765A (zh) | 2019-02-01 | 2025-06-17 | 瑞泽恩制药公司 | 抗IL2受体γ抗原结合蛋白 |
| WO2020257639A1 (en) | 2019-06-21 | 2020-12-24 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| WO2021092075A1 (en) | 2019-11-05 | 2021-05-14 | Medikine Inc. | IL-2RβγC BINDING COMPOUNDS |
| IL292803A (en) | 2019-11-05 | 2022-07-01 | Medikine Inc | Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof |
| CA3161364A1 (en) * | 2019-12-24 | 2021-07-01 | Carl WALKEY | Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor |
| MX2022009390A (es) * | 2020-02-03 | 2022-11-16 | Medikine Inc | Compuestos de unión a il-7r¿¿c. |
| IL295303A (en) | 2020-02-03 | 2022-10-01 | Medikine Inc | 7-il alpha receptor binding compounds and preparations containing them |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| US12187763B2 (en) | 2020-02-11 | 2025-01-07 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| WO2021163369A2 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| KR102627471B1 (ko) | 2020-02-16 | 2024-01-18 | 아울로스 바이오사이언스 인코포레이티드 | 조작된 항-il-2 항체 |
| JP7734693B2 (ja) | 2020-04-29 | 2025-09-05 | イミュニティーバイオ インコーポレイテッド | 抗ｃｄ２６タンパク質及びそれらの使用法 |
| BR102020009679A2 (pt) * | 2020-05-14 | 2021-11-23 | Fundação Universidade Federal Do Abc - Ufabc | Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| IL298608A (en) | 2020-06-01 | 2023-01-01 | Hcw Biologics Inc | Methods of treating aging-related disorders |
| WO2022031890A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Ifngr2 binding molecules and methods of use |
| US11859001B2 (en) | 2020-08-05 | 2024-01-02 | Synthekine, Inc. | IL12RB1-Binding molecules and methods of use |
| BR112023001723A2 (pt) | 2020-08-05 | 2023-05-02 | Synthekine Inc | Moléculas de ligação à gp130 e métodos de uso |
| US12286482B2 (en) | 2020-08-05 | 2025-04-29 | Synthekine, Inc. | IL10RB binding molecules and encoding nucleic acids |
| US12122839B2 (en) | 2020-08-05 | 2024-10-22 | Synthekine, Inc. | IFNGR binding synthetic cytokines and methods of use |
| US20230272094A1 (en) * | 2020-08-05 | 2023-08-31 | Synthekine, Inc. | Il2rb/il2rg synthetic cytokines |
| MX2023001490A (es) | 2020-08-05 | 2023-04-27 | Synthekine Inc | Moleculas de union a il27r\03b1 y metodos de uso. |
| US12291572B2 (en) | 2020-08-05 | 2025-05-06 | Synthekine, Inc. | IL12 receptor synthetic cytokines and methods of use |
| WO2022032023A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il23r binding molecules and methods of use |
| US12077594B2 (en) | 2020-08-05 | 2024-09-03 | Synthekine, Inc. | IL2RG binding molecules and methods of use |
| CN117242088A (zh) | 2020-08-05 | 2023-12-15 | 辛德凯因股份有限公司 | Il10受体结合分子和使用方法 |
| WO2022031885A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10ra binding molecules and methods of use |
| CN116829585A (zh) | 2020-08-05 | 2023-09-29 | 辛德凯因股份有限公司 | Il27受体结合相关的组合物和方法 |
| US12234291B2 (en) | 2020-08-05 | 2025-02-25 | Synthekine, Inc. | IL2RB binding molecules and methods of use |
| WO2022150791A2 (en) * | 2021-01-11 | 2022-07-14 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| CA3209479A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| WO2022187710A1 (en) * | 2021-03-05 | 2022-09-09 | Atreca, Inc. | Epha2 antibodies |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| JPWO2023027177A1 (OSRAM) | 2021-08-26 | 2023-03-02 | ||
| US12202884B2 (en) | 2021-09-17 | 2025-01-21 | Parker Institute For Cancer Immunotherapy | Nucleic acids encoding switch receptors using IL-9 receptor signaling domains |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| JP2024541048A (ja) * | 2021-11-02 | 2024-11-06 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | 抗ｃｄ１２２抗体、抗ｃｄ１３２抗体、及び関連する二重特異性結合性タンパク質 |
| WO2023139293A1 (en) | 2022-01-24 | 2023-07-27 | Novimmune Sa | Composition and methods for the selective activation of cytokine signaling pathways |
| WO2023150733A2 (en) * | 2022-02-04 | 2023-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Surrogate cytokine polypeptides |
| JP2025508939A (ja) | 2022-03-02 | 2025-04-10 | イミュニティーバイオ インコーポレイテッド | 膵臓癌の治療方法 |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024073723A2 (en) * | 2022-09-30 | 2024-04-04 | Forte Subsidiary, Inc. | Anti-cd122 antibodies and uses thereof |
| WO2024086754A2 (en) * | 2022-10-19 | 2024-04-25 | Tentarix Biotherapeutics, Inc. | Multi variable domain therapeutic immunoglobulin |
| WO2024146955A1 (en) | 2023-01-06 | 2024-07-11 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| WO2024146960A1 (en) | 2023-01-06 | 2024-07-11 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| AU2024224039A1 (en) * | 2023-02-22 | 2025-06-26 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-il2ra antibodies and uses thereof |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2310414T3 (es) | 1995-01-09 | 2009-01-01 | Boehringer Ingelheim International Gmbh | Polipeptido asociado a il-2r y moleculas de adn que codifican para este. |
| WO1997043416A1 (en) * | 1996-05-10 | 1997-11-20 | Biogen, Inc. | Common gamma chain blocking agents |
| US20070098685A1 (en) | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
| JP2009542592A (ja) | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法 |
| JP2010513245A (ja) * | 2006-12-14 | 2010-04-30 | アクトジェニックス・エヌブイ | 免疫調節を誘起するための結合分子の送達 |
| WO2011127324A2 (en) * | 2010-04-08 | 2011-10-13 | JN Biosciences, LLC | Antibodies to cd122 |
| EP2847345A1 (en) * | 2012-05-07 | 2015-03-18 | Immune Pharmaceuticals Ltd. | Method of generating human monoclonal antibodies |
| US20140044675A1 (en) * | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| WO2014028560A2 (en) * | 2012-08-14 | 2014-02-20 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP3038657A2 (en) * | 2013-08-28 | 2016-07-06 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| DK3328894T3 (en) | 2015-08-06 | 2019-02-04 | Agency Science Tech & Res | IL2RBETA / COMMON GAMMA CHAIN ANTIBODIES |
-
2016
- 2016-08-05 DK DK16762975.7T patent/DK3328894T3/en active
- 2016-08-05 WO PCT/EP2016/068780 patent/WO2017021540A1/en not_active Ceased
- 2016-08-05 AU AU2016301970A patent/AU2016301970A1/en not_active Abandoned
- 2016-08-05 TR TR2019/01445T patent/TR201901445T4/tr unknown
- 2016-08-05 PT PT16762975T patent/PT3328894T/pt unknown
- 2016-08-05 TW TW105124993A patent/TW201713699A/zh unknown
- 2016-08-05 JP JP2018506135A patent/JP6908591B2/ja active Active
- 2016-08-05 PL PL16762975T patent/PL3328894T3/pl unknown
- 2016-08-05 HU HUE16762975A patent/HUE043421T2/hu unknown
- 2016-08-05 EP EP16762975.7A patent/EP3328894B1/en active Active
- 2016-08-05 CN CN201680046297.2A patent/CN107922496B/zh active Active
- 2016-08-05 EP EP18187373.8A patent/EP3428193B1/en active Active
- 2016-08-05 ES ES16762975T patent/ES2710618T3/es active Active
- 2016-08-05 CA CA2994906A patent/CA2994906A1/en active Pending
- 2016-08-05 CN CN202210993771.XA patent/CN115925939A/zh active Pending
- 2016-08-05 ES ES18187373T patent/ES2841799T3/es active Active
- 2016-08-05 US US15/229,336 patent/US10167338B2/en active Active
- 2016-08-05 KR KR1020187006234A patent/KR102753399B1/ko active Active
- 2016-08-05 US US15/750,425 patent/US10472421B2/en active Active
-
2018
- 2018-02-28 US US15/908,218 patent/US10472423B2/en active Active
- 2018-03-16 US US15/922,921 patent/US10246512B2/en active Active
- 2018-08-24 US US16/112,008 patent/US10696747B2/en active Active
-
2019
- 2019-01-29 CY CY20191100118T patent/CY1121197T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527912A5 (OSRAM) | ||
| JP6707496B2 (ja) | Ａｐｒｉｌバリアント | |
| JP2018508475A5 (OSRAM) | ||
| RU2715628C2 (ru) | Антитела к pd-1 | |
| JP6666905B2 (ja) | Ｐｄ−ｌ１抗体及びその使用 | |
| JP2019519208A5 (OSRAM) | ||
| JP2018138058A (ja) | 間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール | |
| JP2020522261A5 (OSRAM) | ||
| JP2022169504A5 (OSRAM) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| JP2018503600A5 (OSRAM) | ||
| JP2017536111A5 (OSRAM) | ||
| JP2019520034A5 (OSRAM) | ||
| JP6868655B2 (ja) | Ｃｄ６結合パートナーの使用およびそれに基づく方法 | |
| JP2017532005A5 (OSRAM) | ||
| CN115103633B (zh) | 使用多种成像剂的成像方法 | |
| JP2021500916A5 (OSRAM) | ||
| JP2022527941A (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| JP2019535241A5 (OSRAM) | ||
| CN103827144A (zh) | 新的抗cxcr4抗体及其用于检测和诊断癌症的用途 | |
| EP2523687A1 (en) | Methods for diagnosis and treatment of cutaneous t cell lymphomas | |
| JP2023519304A (ja) | 多発性骨髄腫における免疫療法の標的およびその同定方法 | |
| JP2014515600A5 (OSRAM) | ||
| TW201811828A (zh) | 抗原結合分子和使用彼之方法 | |
| CN110809628A (zh) | 使用外周血t细胞的肿瘤细胞毒性活性作为指标预测肿瘤免疫疗法效果的方法 |